<DOC>
	<DOCNO>NCT02951091</DOCNO>
	<brief_summary>In-depth understanding molecular characteristic gastric cancer enable u realize personalized medicine target agent gastric cancer treatment.The investigator initiate open-label , randomize , control phase II , multi-arm trial comparing target therapy base tumor molecular profile standard paclitaxel therapy second line treatment .</brief_summary>
	<brief_title>Biomarker-Integrated Umbrella , Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm locally advanced metastatic gastric cancer gastroesophageal junction cancer 2 . Eastern Cooperative Oncology Group performance status 0 1 3 . Male female ; ≥ 19 year age 4 . On progression 1st line palliative chemotherapy 5 . Subjects evaluable lesion ( use RECIST 1.1 criterion ) 6 . Subjects meet follow criterion : Absolute neutrophil count ≥ 1000 /µL Platelet count ≥ 75,000/ µL Serum creatinine &lt; 1.5 x upper limit normal Creatinine clearance ≥60 mL/min aspartate aminotransferase alanine transaminase 3 x upper limit normal Evidence significant clinical disorder laboratory find make undesirable patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>